Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics.

Paschke R, Cantara S, Crescenzi A, Jarzab B, Musholt TJ, Sobrinho Simoes M.

Eur Thyroid J. 2017 Jul;6(3):115-129. doi: 10.1159/000468519. Epub 2017 May 19.

2.

Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology.

Sciacchitano S, Lavra L, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Trovato M, Drago C, Bartolazzi A.

Oncotarget. 2017 Jul 25;8(30):49421-49442. doi: 10.18632/oncotarget.17220.

3.

The first Canadian experience with the Afirma® gene expression classifier test.

Kay-Rivest E, Tibbo J, Bouhabel S, Tamilia M, Leboeuf R, Forest VI, Hier MP, Savoury L, Payne RJ.

J Otolaryngol Head Neck Surg. 2017 Apr 4;46(1):25. doi: 10.1186/s40463-017-0201-7.

4.

Thyroid Imaging Reporting and Data System Score Combined with the New Italian Classification for Thyroid Cytology Improves the Clinical Management of Indeterminate Nodules.

Ulisse S, Bosco D, Nardi F, Nesca A, D'Armiento E, Guglielmino V, De Vito C, Sorrenti S, Pironi D, Tartaglia F, Arcieri S, Catania A, Monti M, Filippini A, Ascoli V.

Int J Endocrinol. 2017;2017:9692304. doi: 10.1155/2017/9692304. Epub 2017 Mar 1.

5.

Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making.

Kloos RT.

Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):36-49. doi: 10.4274/2017.26.suppl.05.

6.

Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.

Su X, Jiang X, Xu X, Wang W, Teng X, Shao A, Teng L.

Onco Targets Ther. 2016 Apr 27;9:2495-509. doi: 10.2147/OTT.S101800. eCollection 2016.

7.

Cytopathologic diagnosis of fine needle aspiration biopsies of thyroid nodules.

Misiakos EP, Margari N, Meristoudis C, Machairas N, Schizas D, Petropoulos K, Spathis A, Karakitsos P, Machairas A.

World J Clin Cases. 2016 Feb 16;4(2):38-48. doi: 10.12998/wjcc.v4.i2.38. Review.

8.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L.

Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review.

9.

The variable phenotype and low-risk nature of RAS-positive thyroid nodules.

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD Jr, Alexander EK.

BMC Med. 2015 Aug 7;13:184. doi: 10.1186/s12916-015-0419-z.

10.

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.

Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ 3rd, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE; American Thyroid Association Surgical Affairs Committee.

Thyroid. 2015 Jul;25(7):760-8. doi: 10.1089/thy.2014.0502. Epub 2015 Jun 24. Review.

11.

BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.

Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S.

Endocr Relat Cancer. 2015 Apr;22(2):159-68. doi: 10.1530/ERC-14-0531. Epub 2015 Jan 15.

12.

Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.

Fallahi P, Giannini R, Miccoli P, Antonelli A, Basolo F.

Curr Genomics. 2014 Jun;15(3):171-7. doi: 10.2174/1389202915999140404100347.

13.

Can ultrasound be as a surrogate marker for diagnosing a papillary thyroid cancer? Comparison with BRAF mutation analysis.

Seo JY, Kim EK, Baek JH, Shin JH, Han KH, Kwak JY.

Yonsei Med J. 2014 Jul;55(4):871-8. doi: 10.3349/ymj.2014.55.4.871.

14.

Pre-analytic steps for molecular testing on thyroid fine-needle aspirations: The goal of good results.

Rossi ED, Schmitt F.

Cytojournal. 2013 Nov 28;10:24. doi: 10.4103/1742-6413.122300. Review.

15.

Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation.

Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS.

Ann Surg Oncol. 2014 Apr;21(4):1379-83. doi: 10.1245/s10434-013-3450-3. Epub 2013 Dec 31.

16.

Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.

Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60. doi: 10.1210/jc.2013-2292. Epub 2013 Aug 26.

17.

Contribution of the BRAF oncogene in the pre-operative phase of thyroid carcinoma.

Rodrigues HG, DE Pontes AA, Adan LF.

Oncol Lett. 2013 Jul;6(1):191-196. Epub 2013 May 22.

18.

RAS mutations in thyroid cancer.

Howell GM, Hodak SP, Yip L.

Oncologist. 2013;18(8):926-32. doi: 10.1634/theoncologist.2013-0072. Epub 2013 Jul 19. Review.

19.

Progress in molecular-based management of differentiated thyroid cancer.

Xing M, Haugen BR, Schlumberger M.

Lancet. 2013 Mar 23;381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9. Epub 2013 Mar 22. Review.

20.

Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines.

Ahmadieh H, Azar ST.

J Thyroid Res. 2012;2012:512401. doi: 10.1155/2012/512401. Epub 2012 Dec 30.

Supplemental Content

Support Center